CIPLA
Cipla Limited
Each stock's 10,000-path forecast, rendered as light.
Cipla Limited (CIPLA) Stock Analysis & Case Study
Is CIPLA a good buy? The data-driven verdict.
Cipla Limited (CIPLA) trades at ₹1,464,on the numbers it mixed signals, a Downstox Snapshot Score of 50/100.
On the numbers, Cipla Limited (CIPLA) mixed signals, a Downstox Snapshot Score of 50/100, weighing premium at 33.0× earnings, ROE of 11.6%, a 67% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
CIPLA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How CIPLA ranks against the 2,373 companies in our screener
- CIPLA's market cap of 1.18L Cr ranks in the top 4% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CIPLA's book value of ₹426 ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CIPLA's promoter holding of 29.2% ranks in the 7th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CIPLA's 3-year profit (PAT) growth of 10.0% ranks in the 42nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CIPLA's 3-year revenue growth of 7.0% ranks in the 41st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CIPLA's debt-to-equity ratio of 0.02x is lower than 94% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is CIPLA overvalued? CIPLA P/E vs its Pharma
CIPLA's P/E of 33.0× sits above the Pharma peer median of 33.0×, so on earnings it screens in line with peers, while its 0.89% dividend yield is above the peer median of 0.68%.
CIPLA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of CIPLA history (10%/yr drift, 22%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| CIPLA 2027 | ₹1,217 | ₹1,611 | ₹2,134 | +10% |
| CIPLA 2028 | ₹1,191 | ₹1,773 | ₹2,641 | +21% |
| CIPLA 2029 | ₹1,196 | ₹1,952 | ₹3,186 | +33% |
| CIPLA 2030 | ₹1,230 | ₹2,148 | ₹3,751 | +47% |
| CIPLA 2031 | ₹1,257 | ₹2,364 | ₹4,446 | +61% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability CIPLA goes up, or doubles?
The bull case for CIPLA
- A 10,000-path probability model puts a 67% chance the price is higher in a year, with a median target of ₹1,611 (+10%).
- Relatively low volatility (22%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,186.
The bear case & risks
- CIPLA's P/E of 33.0x is lower than 42% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CIPLA's return on equity of 11.6% ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,196.
CIPLA volatility & expected range, how bumpy is the ride?
Over the last 9.8 years CIPLA compounded at 10%/year with annualized volatility of 22%. That volatility implies a 1-year 80% range of ₹1,217-₹2,134, the honest backbone behind any single price target.
CIPLA price forecast, the full 60-month probability fan
CIPLA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds CIPLA hits common targets within the simulated horizon?
Full multi-horizon detail on the CIPLA price target & forecast page.
CIPLA Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. CIPLA scores 6/8, mixed financial health.
CIPLA MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy CIPLA with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 23.00% | 4.3× |
| Zerodha | 22.60% | 4.4× |
| Groww | 22.56% | 4.4× |
| Dhan | 22.00% | 4.5× |
| Kotak NeoCHEAPEST | 20.00% | 5.0× |
| Paytm Money | 20.28% | 4.9× |
| Pocketful | 26.50% | 3.8× |
| Fyers | 27.03% | 3.7× |
| Anand Rathi | 26.50% | 3.8× |
| Bajaj Broking | 23.00% | 4.3× |
| Share India | 26.50% | 3.8× |
Compare every broker on the CIPLA MTF page.
CIPLA vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| CIPLA (this stock) | 33.0× | 0.89% | ₹1.18L Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
| BIOCON | 95.5× | 0.12% | ₹69,482 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About Cipla Limited: sector, index & market-cap context
Cipla Limited (CIPLA) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 50 index, with a market capitalisation of ₹1.18L Cr. See more stocks on our screener.
How the CIPLA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Cipla Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
CIPLA analysis, FAQs
Is Cipla Limited (CIPLA) a good buy?
On the numbers, Cipla Limited (CIPLA) mixed signals, a Downstox Snapshot Score of 50/100, weighing premium at 33.0× earnings, ROE of 11.6%, a 67% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is CIPLA overvalued or undervalued?
CIPLA trades at 33.0× earnings versus a peer median of 33.0×, so it screens richer than its Pharma peers.
What is the CIPLA share price target for 2031?
CIPLA's probability-weighted 2031 median target is ₹2,364, with an 80% range of ₹1,257-₹4,446 (10,000-path Monte-Carlo).
What is the probability CIPLA doubles in 5 years?
The modelled probability of CIPLA reaching ₹2,928 (2×) within 5 years is 34%.
What is the bull case for CIPLA?
A 10,000-path probability model puts a 67% chance the price is higher in a year, with a median target of ₹1,611 (+10%). Relatively low volatility (22%/yr), a steadier ride than the typical mid/small-cap.
What are the risks in CIPLA?
CIPLA's P/E of 33.0x is lower than 42% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. CIPLA's return on equity of 11.6% ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.